Ayca Sezer is a seasoned professional with over 20 years of experience in the pharmaceuticals industry, currently serving as the Director of Business Development at SPIMACO. In this pivotal role, Ayca leverages her extensive expertise in strategic planning and portfolio management to drive growth and...
Ayca Sezer is a seasoned professional with over 20 years of experience in the pharmaceuticals industry, currently serving as the Director of Business Development at SPIMACO. In this pivotal role, Ayca leverages her extensive expertise in strategic planning and portfolio management to drive growth and innovation within the organization. Her proficiency in licensing—both in and out—enables SPIMACO to expand its market reach and enhance its product offerings, ensuring that the company remains competitive in a rapidly evolving landscape.
At SPIMACO, Ayca has spearheaded several key projects that underscore her strategic acumen and ability to navigate complex regulatory environments. Her work in business case preparation has been instrumental in identifying lucrative opportunities across multi-country markets, allowing the company to make informed decisions that align with its long-term objectives. Additionally, her skills in key account management and market analysis have facilitated the development of tailored marketing strategies that resonate with diverse customer segments.
Ayca's comprehensive understanding of pharmacovigilance and regulatory affairs further enhances her capability to manage the lifecycle of pharmaceutical products effectively. By integrating her knowledge of medical devices and validation processes, she ensures that SPIMACO adheres to the highest standards of quality and compliance. As a leader, Ayca is committed to fostering collaboration across teams, driving initiatives that not only enhance operational efficiency but also contribute to the overall mission of delivering innovative healthcare solutions. Her strategic vision and dedication to excellence position her as a key player in shaping the future of SPIMACO and the broader pharmaceutical industry.
